Phase 2 Start
COLL: Phase 2 Start: Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind
April 1, 2027 · psilocybin. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- April 1, 2027
- Company
- COLLEGIUM PHARMACEUTICAL, INC (COLL)
- Drug
- psilocybin
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 2 Start~month
Phase 2 Start: Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind
- Drug
- psilocybin
- Indication
- Opioid Use Disorder